ArticleScientific reports2025
External multicenter validation of the eSAH score for predicting outcomes after subarachnoid hemorrhage.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reliable assessment of prognosis after aneurysmal subarachnoid hemorrhage (SAH) is essential to inform clinical decision-making and prevent premature assumptions of poor outcome. The enhanced SAH (eSAH) score combines three routinely available variables-age, Glasgow Coma Scale (GCS), and subarachnoid hemorrhage blood volume (SAHV)-to provide an objective framework for early outcome stratification. SAHV is estimated using the ABC/2-derived ellipsoid method applied across five major cisternal compartments on non-contrast CT. While the eSAH score has shown promise in initial derivation studies, its external performance and calibration have not yet been validated across diverse healthcare settings. We conducted a retrospective cohort study using consecutive data from two high-volume tertiary centers: one in a high-income country (the United States) and one in a middle-income country (Brazil). Non-aneurysmal SAH cases were excluded. The eSAH score was validated to predict discharge functional outcomes (modified Rankin Scale, mRS) and mortality, using discrimination (area under the ROC curve, AUC) and calibration metrics and was compared to the World Federation of Neurosurgical Societies (WFNS) score. A total of 472 patients were included. The eSAH score demonstrated moderate discriminative performance, with AUCs of 0.78 for unfavorable functional outcome and 0.799 for in-hospital mortality. Each one-point increase in the score was associated with a 2.14-fold increase in the odds of poor outcome (95% CI, 1.84-2.50; p < 0.0001) and a 2.14-fold increase in the odds of mortality (95% CI, 1.78-2.57; p < 0.001). The WFNS score yielded slightly lower AUCs (0.76 and 0.75, respectively). The eSAH score provides a simple, generalizable framework for early prognostication after aneurysmal SAH, performing consistently across two markedly different healthcare systems. Although its discriminative power remains moderate, its objective structure and reliance on measurable imaging features make it ideally suited for integration with artificial intelligence to enable automated, precise, and scalable SAHV quantification. Such integration may substantially enhance prognostic accuracy and support more equitable, data-driven neurocritical care worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.